Nanotechnology approaches for personalized treatment of multidrug resistant cancers

• Published in: Advanced drug delivery reviews Vol. 65; no. 13-14; pp. 1880 - 1895
• Main Authors: Minko, Tamara, Rodriguez-Rodriguez, Lorna, Pozharov, Vitaly
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.11.2013
• Subjects: Animals; Antibody; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - therapeutic use; Antisense oligonucleotides; Cancer stem cells; CD44; Dose-Response Relationship, Drug; Drug delivery system; Drug Delivery Systems; Drug Resistance, Multiple - drug effects; Drug Resistance, Neoplasm - drug effects; Endocytosis - drug effects; Humans; LHRH; Molecular Targeted Therapy; Nanotechnology - methods; Neoplasms - drug therapy; Neoplasms - metabolism; Neoplasms - pathology; Passive and active targeting; Peptides; Precision Medicine - methods; Pump and nonpump resistance; siRNA; ABC; NLC; Peptides; Antibody; CPT; EPR; DBD; Antisense oligonucleotides; siRNA; TMD; DOX; PAMAM; LHRH; NBD; Passive and active targeting; DDS; TPADDS; SNP; Pump and nonpump resistance; Cancer stem cells; ASO; Drug delivery system; CD44; IC50 dose; targeted proapoptotic drug delivery system; enhanced permeability and retention effect; small interfering RNA; IC dose; transmembrane domain; drug-binding domain; doxorubicin; single-nucleotide polymorphism; nucleotide-binding domain; luteinizing hormone-release hormone; a dose that kills 50% of cells; poly(amido amine); camptothecin; adenosine triphosphate (ATP)-binding cassette; nanostructured lipid carriers
• ISSN: 0169-409X; 1872-8294; 1872-8294
• DOI: 10.1016/j.addr.2013.09.017

The efficacy of chemotherapy is substantially limited by the resistance of cancer cells to anticancer drugs that fluctuates significantly in different patients. Under identical chemotherapeutic protocols, some patients may receive relatively ineffective doses of anticancer agents while other individuals obtain excessive amounts of drugs that induce severe adverse side effects on healthy tissues. The current review is focused on an individualized selection of drugs and targets to suppress multidrug resistance. Such selection is based on the molecular characteristics of a tumor from an individual patient that can potentially improve the treatment outcome and bring us closer to an era of personalized medicine. [Display omitted]